A randomized, open-label, controlled trial for the efficacy and safety of Farpiravir Tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029996

Enrollment

Unknown

Registered

2020-02-20

Start date

2020-02-20

Completion date

Unknown

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Low-dose group:Tablets

200mg

oral

twice a day

The adult dose is 1600 mg per time on first day

the duration of treatment will be 10 d.

Middle-dose group:Tablets

orally

The adult dose is 1800 mg per time on first day

High-dose group:Tablets

The adult dose is 2400 mg per time on first day

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntarily sign the Consent Form; 2. Male or female aged 18 and over; 3. According to the "Diagnosis and Treatment Scheme for Pneumonia of Novel coronavirus pneumonia Infection-Trial Fifth Edition", inpatient diagnosed with Novel coronavirus pneumonia diagnosed and clinical classification of ordinary type: Inpatients with fever (underarm temperature >= 37.0 degree C), respiratory tract, etc. Imaging shows pneumonia.

Exclusion criteria

Exclusion criteria: 1. Females who are pregnant or likely to be pregnant, or who are lactating and unable to stop breastfeeding, or who have positive pregnancy tests during screening; 2. Males or females who have a birth plan or are unwilling to take reliable contraceptive measures for contraception within 90 days from signing the informed consent to the last dose; 3. Other circumstances that the researchers consider inappropriate for participation in this study.

Design outcomes

Primary

Measure	Time frame
Time to Clinical Recovery;	—

Secondary

Measure	Time frame
The incidence of common Novel coronavirus pneumonia progressing to severe;Release and quarantine time;Time when common Novel coronavirus pneumonia progress to severe;Proportion to ICU;Mechanical ventilation rate;mortality rate;Time for the main clinical manifestations to subside (fever, dry cough, fatigue);Duration of fever;Changes in viral load over time;Time for the virus to turn negative;	—

Countries

China

Contacts

Public ContactZhaohui Tong

Beijing Chaoyang Hospital, Capital Medical University

13910930309@163.com+86 13910930309

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026